A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

February 6, 2006

Primary Completion Date

January 10, 2008

Study Completion Date

January 13, 2017

Conditions
Metastatic Breast Cancer
Interventions
DRUG

fulvestrant

500 mg intramuscular injection

DRUG

anastrozole

1 mg oral tablet

Trial Locations (41)

1233

Research Site, Sofia

1527

Research Site, Sofia

1784

Research Site, Sofia

2700

Research Site, Blagoevgrad

3000

Research Site, Vratsa

4000

Research Site, Plovdiv

5000

Research Site, Veliko Tarnovo

9000

Research Site, Varna

9700

Research Site, Shumen

14004

Research Site, Córdoba

21701

Research Site, Frederick

25198

Research Site, Lleida

36002

Research Site, Pontevedra

63113

Research Site, St Louis

75137

Research Site, Duncanville

78705

Research Site, Austin

80131

Research Site, Napoli

86000

Research Site, Poitiers

92210

Research Site, Saint-Cloud

07666

Research Site, Teaneck

14784-400

Research Site, Barretos

30380-490

Research Site, Belo Horizonte

74000-000

Research Site, Goiânia

17210-120

Research Site, Jaú

20560-120

Research Site, Rio de Janeiro

01219-010

Research Site, São Paulo

656 53

Research Site, Brno

656 91

Research Site, Brno

506 43

Research Site, Jičín

708 52

Research Site, Ostrava

140 00

Research Site, Prague

401 13

Research Site, Ústí nad Labem

06100

Research Site, Nice

07100

Research Site, Sassari

31-115

Research Site, Krakow

10-228

Research Site, Olsztyn

08003

Research Site, Barcelona

08025

Research Site, Barcelona

DE22 3DT

Research Site, Derby

DD1 9SY

Research Site, Dundee

EH4 2XU

Research Site, Edinburgh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY